Oncology biotech BioAtla banks $30M from Chinese syndicate

San Diego's BioAtla has raised $30 million in equity from undisclosed Chinese investors, cash that will help push its pipeline of large-molecule treatments. The company is at work on what it calls conditionally active biologics, or CABs, which are immunotherapeutics that can be switched on in the presence of certain antigens, according to BioAtla. With the new cash, the company plans to accelerate its in-house pipeline of CAB products toward clinical development, all the while leaning on its new Chinese partners to help forge new relationships in that country. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.